Mycophenolate Mofetil for the Treatment of Cutaneous Lupus Erythematosus With Smoldering Systemic Involvement

2002 ◽  
Vol 138 (12) ◽  
pp. 1616-1618 ◽  
Author(s):  
N. M. Hanjani
Keyword(s):  
Mycophenolate Mofetil ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Systemic Involvement ◽  
Cutaneous Lupus

scholarly journals Atypical and Rare Forms of Cutaneous Lupus Erythematosus: The Importance of the Diagnosis for the Best Management of Patients

Dermatology ◽  
2021 ◽  
pp. 1-10
Author(s):  
Astrid Herzum ◽  
Giulia Gasparini ◽  
Emanuele Cozzani ◽  
Martina Burlando ◽  
Aurora Parodi
Keyword(s):  
General Practitioner ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Cutaneous Manifestations ◽  
Skin Manifestation ◽  
Systemic Involvement ◽  
Best Management ◽  
Wide Range ◽  
Cutaneous Lupus

Lupus erythematosus (LE) is an autoimmune disease with a wide range of clinical and cutaneous manifestations. Along with the well-known typical cutaneous manifestations of LE, some cutaneous manifestations are rarer, but still characteristic, enabling the dermatologist and the general practitioner who know them to suspect cutaneous LE (CLE) and investigate a possible underlying systemic involvement. Indeed, not infrequently a skin manifestation is the first presentation of systemic LE (SLE), and >75% of SLE patients show signs of skin disease during the course of the illness. Especially, SLE involvement occurs in cases of acute CLE, while it is uncommon in subacute CLE and rare in chronic CLE. This review aims to concentrate especially on atypical cutaneous manifestations of LE to enable the clinician to diagnose even the rarest forms of CLE.

scholarly journals Management and obstetric prognosis of pregnancy with isolated cutaneous lupus

2020 ◽  
Vol 11 (e) ◽  
pp. e129.1-e129.4
Author(s):  
Aida Oulehri ◽  
Hanane Baybay ◽  
Soukaina Chhiti
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Fetal Loss ◽  
Insufficient Data ◽  
Systemic Lupus ◽  
Fetal Outcomes ◽  
Systemic Involvement ◽  
Increased Risk ◽  
Cutaneous Lupus

It is well known that pregnancy in a woman with systemic lupus erythematosus (SLE) is associated with an increased risk of adverse maternal and fetal outcomes. But what about the risk in patients with isolated cutaneous lupus erythematosus (CLE) during pregnancy? There are insufficient data on clinical obstetrical and neonatal outcomes in women with CLE and very few studies have been published concerning the obstetric prognosis in the various types of cutaneous lupus. We report the case of a 24-year-old woman with no known pathological history, who presented with a severe and inaugural flare-up of a typical acute lupus erythematosus (ACLE) without systemic involvement which was complicated by a fetal loss.

scholarly journals Linear cutaneous lupus erythematosus in children—report of two cases and review of the literature: A case report

2020 ◽  
Vol 8 ◽  
pp. 2050313X2097920
Author(s):  
Darosa Lim ◽  
Afshin Hatami ◽  
Victor Kokta ◽  
Maryam Piram
Keyword(s):  
Differential Diagnosis ◽  
Case Report ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Review Of The Literature ◽  
Inflammatory Lesions ◽  
Systemic Involvement ◽  
Children And Young Adults ◽  
Blaschko’S Lines ◽  
Cutaneous Lupus

Linear cutaneous lupus erythematosus is an unusual presentation of cutaneous lupus following Blaschko’s lines. It is described mostly in children and young adults and is usually not associated with systemic involvement. We report two cases of linear cutaneous lupus erythematosus in children who significantly improved after treatment with hydroxychloroquine in combination with topical corticosteroids and tacrolimus. These rare cases underline the importance of including linear cutaneous lupus erythematosus in the differential diagnosis of blaschkoid inflammatory lesions.

scholarly journals Isoniazid - induced chronic cutaneous Lupus erythematosus

2016 ◽  
Vol 13 (1) ◽  
pp. 52-56
Author(s):  
A Chiriac ◽  
P Brzezinski ◽  
A E Chiriac ◽  
L Foia ◽  
D Mihaila ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Histopathological Examination ◽  
Cutaneous Lupus Erythematosus ◽  
Clinical Aspects ◽  
Direct Immunofluorescence ◽  
Drug Induced ◽  
Systemic Involvement ◽  
Antituberculosis Therapy ◽  
The Face ◽  
Cutaneous Lupus

A 23-year-old man developed drug-induced chronic cutaneous lupus erythematosus 8 months after isoniazid (INH) therapy for pulmonary tuberculosis. Diagnosis was based on clinical aspects (discoid lesions on the face, erythema, photosensitivity, hyperpigmentation), histopathological examination, along with direct immunofluorescence examination (DIF), the absence of systemic involvement and the routine laboratory parameters, which registered all within normal range. Hydroxychloroquine therapy associated to photo protection and emollients determined the clear up of the facial eruption within six months. Transient residual hyperpigmentation could be noticed 2 months after discontinuation of the treatment. This case illustrates a rare form of drug-induced chronic cutaneous lupus erythematosus developed 2 months after withdrawal of antituberculosis therapy, with excellent results with hydroxychloroquine.NJDVL Vol. 13, No. 1, 2015 Page: 52-56

scholarly journals Mycophenolate Mofetil in Refractory Cutaneous Lupus Erythematosus: No Definitive Evidence

2016 ◽  
Vol 43 (9) ◽  
pp. 1766.1-1766 ◽  
Author(s):  
CLAUDE BACHMEYER ◽  
SIMON GALMICHE ◽  
ANTOINE FAYAND ◽  
ALEXANDRE DEGACHI ◽  
SOPHIE GEORGIN-LAVIALLE
Keyword(s):  
Mycophenolate Mofetil ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Definitive Evidence ◽  
Cutaneous Lupus
Sign in / Sign up

Export Citation Format

Share Document